Oyster Point’s Tyrvaya Nasal Spray for Dry Eye Disease is Now Available at US Regional Wholesalers

Oyster Point Pharma announced that Tyrvaya (varenicline solution) Nasal Spray 0.03 mg is now available at US regional wholesalers for distribution to pharmacies. The FDA approved Tyrvaya Nasal Spray for the treatment of the signs and symptoms of dry eye disease on October 15, 2021. Tyrvaya Nasal Spray is a highly selective cholinergic agonist delivered twice daily as an aqueous nasal spray into each nostril to activate basal tear production. Nasal spray administration provides a new way to treat dry eye disease without administering medication onto an already irritated ocular surface. In addition, nasal delivery may allow some patients who have difficulty administering topical eye drops to administer independently their prescribed dry eye disease therapy.

“We understand the impact that dry eye disease can have on patients. The urgency to provide a new treatment option for the millions of patients who live with it each day has underscored our efforts to bring Tyrvaya Nasal Spray to pharmacies quickly," John Snisarenko, Chief Commercial Officer of Oyster Point Pharma, said in a company news release. “Oyster Point is committed to supporting the dry eye disease community by supporting access to medication for appropriate patients.”

The company has launched a patient support program called TEAMTyrvaya. For more information on the program and how to enroll, please visit www.Tyrvaya-Pro.com.